Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: Systematic review
BMJ Oct 11, 2018
Matthews A, et al. - In women with a history of non-metastatic breast cancer, researchers examined the impact of endocrine therapies on a wide range of specific clinical cardiovascular disease outcomes. The totality of the randomized controlled trial and observational evidence suggested an increased risk of venous thromboembolism in tamoxifen users vs both non-users and aromatase inhibitor users. Data also indicated a higher risk of vascular diseases, myocardial infarction, and angina in...
To read this article Sign up / Login for free
- Stay on top of policy changes & daily news that matter to you as a healthcare professional
- Update yourself with quick summaries from reputed journals in your specialty
- Earn from paid surveys and influence new developments in healthcare
- Participate in daily quizzes to improve skills and compete with peers
- Save yourself time, as we bring you these and more useful features all at one place!
You get a FREE lifetime membership, with a simple one-time sign up process!